Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.

Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of

Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting

Avacta Group PLC (AIM: AVCT) unveiled encouraging new clinical data for its lead oncology candidate AVA6000 (faridoxorubicin) at the ASCO 2026 annual meeting, highlighting both promising efficacy and a potentially

Avacta Therapeutics (AIM: AVCT) has announced a boardroom transition, with Richard Hughes to be appointed non-executive chairman following the company’s Annual General Meeting on 22 June 2026.

Avacta Group plc has reported significant progress across its pre|CISION oncology platform in its unaudited preliminary results for the year ended December 31, 2025, as the company advances multiple cancer

Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with

LONDON and PHILADELPHIA – April 9, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today provides a business update through the first

LONDON and PHILADELPHIA – April 8, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to extend an open invitation for